Ikena Oncology appoints Richard Wooster to board of directors; board increases to 8

ImageneBio, Inc.

Richard Wooster, Ph.D., appointed to fill new vacancy, effective Jan. 21, 2022; board expands from 7 to 8.
Wooster qualifies as independent director; receives option for 29,200 shares vesting over 3 years.
He brings 30+ years oncology drug discovery experience; discovered BRCA2 gene, co-discovered BRAF mutations.
Most recently CSO at Translate Bio (acquired by Sanofi 2021); previously VP at GSK.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard Wooster

Director

IMA · ImageneBio, Inc.

Effective: 2022-01-21
Filed: January 26, 2022, 6:59 PM ET

On January 21, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Dr. Richard Wooster to fill a newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Wooster was appointed as Director at ImageneBio, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 21, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Dr. Richard Wooster to fill a newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.

View on SEC.gov

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-017680

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.